Browsing Category
Pharma Industry News
4667 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
DEGEVMA approval strengthens Teva biosimilar pipeline as company shifts beyond traditional generics
Teva wins FDA approval for DEGEVMA, expanding its U.S. denosumab biosimilar portfolio as competition intensifies around Xgeva.
Mirum wins Atebrioz FDA approval after $16m Incyte licence in rare FOP market
Mirum Pharmaceuticals has secured FDA approval for Atebrioz in patients aged 12 and older with fibrodysplasia ossificans progressiva, only months after licensing zilurgisertib from Incyte for $16 million upfront plus milestones and royalties.
Avacta wins pre|CISION R&D award, but AVA6103’s H1 2027 efficacy test matters more
Avacta Group plc has moved AVA6103 into its fourth Phase 1 dose level after early human data supported the intended controlled-release mechanism of its pre|CISION platform. The next valuation test is shifting from pharmacokinetic validation to whether higher payload exposure produces meaningful antitumour activity.
Joenja moves closer to broader pediatric APDS label as Pharming Group builds second growth franchise
Pharming Group wins FDA Priority Review for lower-dose Joenja in children with APDS as the fast-growing rare-disease franchise expands.
Novo Nordisk signs €1.17bn Nanexa deal targeting monthly obesity injections
Novo Nordisk has licensed Nanexa's PharmaShell platform for as many as five programmes as competition shifts from weight loss alone toward convenience and dosing frequency.
Legend Biotech adds five-year durability to CARVYKTI’s rapidly growing commercial story
Legend Biotech reports five-year CARVYKTI remissions as sales rise 50%, strengthening the case for earlier use in multiple myeloma.
Efzofitimod returns to pivotal development as aTyr Pharma targets narrower sarcoidosis population
aTyr Pharma gains FDA alignment for a redesigned efzofitimod Phase 3 trial, but financing and clinical validation remain major hurdles.
ADARx Pharmaceuticals jumps in Nasdaq debut after upsized $446.3m IPO
ADARx Pharmaceuticals has completed one of the larger biotechnology flotations of 2026, pricing an upsized $446.3 million Nasdaq offering at the top of its range before shares opened 30% above the IPO price.
Nanexa shares explode 122% after €1.17 billion Novo Nordisk injection deal
Nanexa shares more than doubled after Novo Nordisk signed a global licensing agreement worth up to €1.165 billion for technology designed to turn peptide medicines into monthly or quarterly injections.
Oruka Therapeutics builds long-acting psoriasis case as ORKA-001 clearance deepens without redosing
ORKA-001 reaches 71.4% complete psoriasis clearance without redosing as Oruka Therapeutics advances its long-acting biologic toward Phase 3.